公开(公告)号：US20200276169A1

公开(公告)日：2020-09-03

申请号：US16823485

申请日：2020-03-19

Applicant: Novartis AG

Inventor： Virender Singh AULAKH ,  Anthony CASAREZ ,  Xiaodong LIN ,  Mika LINDVALL ,  Glenn MCENROE ,  Heinz Ernst MOSER ,  Folkert RECK ,  Meiliana TJANDRA ,  Robert Lowell SIMMONS ,  Aregahegn YIFRU ,  Qingming ZHU

IPC: A61K31/427 ,  A61K45/06 ,  C07D487/04 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  C07D417/14

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

公开(公告)号：US20190231752A1

公开(公告)日：2019-08-01

申请号：US16380243

申请日：2019-04-10

Applicant: Novartis AG

Inventor： Virender Singh AULAKH ,  Anthony CASAREZ ,  Xiaodong LIN ,  Mika LINDVALL ,  Glenn MCENROE ,  Heinz Ernst MOSER ,  Folkert RECK ,  Meiliana TJANDRA ,  Robert Lowell SIMMONS ,  Aregahegn YIFRU ,  Qingming ZHU

IPC: A61K31/427 ,  A61K31/433 ,  C07D487/04 ,  A61K31/4545 ,  A61K31/496 ,  C07D417/14 ,  A61K31/4439 ,  A61K31/454 ,  A61K45/06

CPC classification number: A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K45/06 ,  C07D417/14 ,  C07D487/04 ,  Y02A50/473 ,  Y02A50/481

Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

公开(公告)号：US20190177324A1

公开(公告)日：2019-06-13

申请号：US16323668

申请日：2017-09-28

Applicant: Novartis AG

Inventor： Anthony CASAREZ ,  Markus FUREGATI ,  Guido KOCH ,  Xiaodong LIN ,  Flavio OSSOLA ,  Folkert RECK ,  Robert Lowell SIMMONS ,  Qingming ZHU

IPC: C07D471/18 ,  A61P31/04 ,  A61K31/439 ,  A61K31/4545 ,  A61K31/427 ,  A61K31/546 ,  A61K31/407 ,  A61K31/496

Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.

公开(公告)号：US20180086762A1

公开(公告)日：2018-03-29

申请号：US15718571

申请日：2017-09-28

Applicant: Novartis AG

Inventor： Anthony CASAREZ ,  Markus FUREGATI ,  Guido KOCH ,  Xiaodong LIN ,  Flavio OSSOLA ,  Folkert RECK ,  Robert Lowell SIMMONS ,  Qingming ZHU

IPC: C07D471/18 ,  A61K31/439 ,  A61K31/431 ,  A61K31/427 ,  A61K31/546 ,  A61K31/407 ,  A61K31/496

CPC classification number: C07D471/18 ,  A61K31/407 ,  A61K31/427 ,  A61K31/431 ,  A61K31/439 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/535 ,  A61K31/546 ,  A61K31/551 ,  A61K45/06 ,  A61P31/04 ,  C07B2200/13 ,  A61K2300/00

Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.